Background
Methods
Search strategy
Study selection and inclusion criteria
Data extraction and quality assessment
Statistical analyses
Results
Selection of eligible studies
Study characteristics
No.of Refs. | Authors (year) | Country | Inclusion period | Study design | Number of cases (F/M) | Median Age (years) (range) | Tumor type (stage) | Treatment | LMR cutoff value | Follow-up period (months) | End points | Analysis of hazard ratio | Adjusted variables | Quality score |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | Chen et al. (2015) | China | 2011–2013 | Retrospective | 253 (104/149) | 65.2 | Non-Small Cell Lung Cancer (IIIB, IV) | Molecular targeted | 3.29 | 24.02 | PFS, OS | Multivariable | Distant metastasis, Malignant effusion, PS | 8 |
17 | Qi et al. (2015) | China | 2011–2013 | Retrospective | 211 (134/77) | 61.2 | Pancreatic cancer (III, IV) | Chemo | 3.3 | NR | OS | Multivariable | Tumor stage, CA19-9 | 7 |
18 | Song et al. (2015) | Korea | 2006–2013 | Retrospective | 177 (83/94) | 52 (25–81) | Colorectal cancer (IV) | Herbal medication, Acupuncture | 3.4 | 3.1 (0.1–33.3) | OS | Multivariable | mGPS, CA19-9, Aspartate aminotransferase, Korean medicine treatment duration | 7 |
19 | Jiang et al. (2015) | China | 2003–2009 | Retrospective | 672 (546/126) | 46 (13–79) | Nasopharyngeal carcinoma (IV) | Chemo, Radio | 2.475 | NR | OS | Multivariable | N stage, No. of metastatic lesions, Liver metastasis | 7 |
4 | Lin et al. (2014) | China | 2006–2010 | Retrospective | 256 (179/77) | 53.6 (35–69) | Nasopharyngeal carcinoma (IV) | Chemo | 5.07 | 22.6 (5.1–42.3) | OS | Multivariable | Age, ECOG performance status, Liver metastasis, No. of metastatic sites | 8 |
15 | Facciorusso et al. (2016) | Italy | 2003–2012 | Retrospective | 127 (88/39) | 66 (38–88) | Colorectal cancer (IV) | RF ablation | 3.96 | 63 (54–71) | OS | Multivariable | Neutrophil-to-lymphocyte ratio, CEA, No. of nodules, Max diameter | 8 |
5 | Minami et al. (2017) | Japan | 2007–2017 | Retrospective | 152 (57/95) | 70.3 | Non-Small Cell Lung Cancer (III, IV) | Molecular targeted | 5.09 | NR | PFS, OS | Multivariable | Distant metastasis, ECOG PS, BMI, EGFR-TKI line, Ccr, Sodium, LDH, CRP | 6 |
20 | Zhu et al. (2017) | China | 2008–2015 | Retrospective | 672 | 55 (30–70) | Epithelial ovarian cancer (III, IV) | Chemo | 3.45 | 38 (5–103) | PFS, OS | Multivariable | FIGO stage, CA-125, Chemosensitivity, Residual tumor | 8 |
21 | Li et al. (2016) | China | 2003–2004 | Retrospective | 424 | 47 (18–74) | Cervical carcinoma (II-IV) | Radio, Chemo | 5.28 | 73 | PFS, OS | Multivariable | HPV DNA status, FIGO classification, pathological type, Lymph node status classification | 8 |
22 | Fukuda et al. (2018) | Japan | 1986–2015 | Retrospective | 152 (109/43) | 64 | Renal cell carcinoma (IV) | Surgery | 3.23 | 14 | OS | Univariate | – | 8 |
23 | Li et al. (2017) | China | 2008–2014 | Retrospective | 122 | NR | Hepatocellular carcinoma (III) | Surgery | 3 | NR | OS | Multivariable | Barcelona clinic liver cancer, Tumor size, Tumor stage, Pathological differentiation | 7 |
24 | Peng et al. (2017) | China | 2000–2012 | Retrospective | 150 (97/53) | 58 (20–82) | Colorectal cancer (IV) | Chemo, Surgery | 2.82 | 36 (2–126) | OS | Multivariable | Age, Lymph node metastases, Timing of metastasis, No. of metastatic tumors, Largest tumor size, Tumor distribution | 8 |
14 | Yang et al. (2017) | China | 2009–2015 | Retrospective | 95 (58/37) | 56 (27–86) | Colorectal cancer (IV) | Chemo, Molecular targeted | 4 | 40 (12–72) | PFS, OS | Univariate | – | 8 |
6 | Lin et al. (2014) | China | 2004–2012 | Retrospective | 370 (213/157) | 63.6 (36–72) | Non-Small Cell Lung Cancer (IIIB, IV) | Chemo | 4.56 | NR | PFS, OS | Multivariable | Histology | 6 |
25 | Neal et al. (2015) | UK | 2006–2010 | Retrospective | 302 (192/110) | 64.8 (26–85) | Colorectal cancer (IV) | Surgery | 2.35 | 29.7 (4–96) | OS | Univariate | – | 8 |
26 | Wu et al. (2016) | China | 2009–2013 | Retrospective | 221 | NR | Rectal cancer (III) | Surgery | 5.13 | NR | OS | Multivariable | Age, CEA, Tumor location, Differentiation, Vascular invasion, Perineural invasion | 7 |
7 | Lin et al. (2016) | China | 2005–2013 | Retrospective | 488 (266/222) | 54 (37–72) | Colorectal cancer (IV) | Chemo | 3.11 | 23.5 (4.3–32.8) | PFS, OS | Multivariable | Gender, ECOG performance status, No. of metastatic sites, Tumor differentiation | 8 |
27 | Gu et al. (2016) | China | 2006–2013 | Retrospective | 161 (128/33) | 56 (17–83) | Renal cell carcinoma (IV) | Surgery | 3.23 | NR | OS | Multivariable | T stage, Fuhrman grade, Histology, Tumor necrosis, Targeted therapy, Hemoglobin c | 6 |
8 | Xiong et al. (2017) | China | 2012–2015 | Retrospective | 78 (36/42) | 59 (28–82) | Lung adenocarcinoma (IIIB, IV) | Chemo | 4.3 | 15.3 (1.7–37.6) | PFS, OS | Multivariable | Gender, Smoking status, Clinical response, No. of metastasis organs | 8 |
49 | Yu et al. (2017) | China | 2010–2013 | Retrospective | 139 (83/56) | NR | Pancreatic cancer (III, IV) | Chemo | 3.19 | 78 | OS | Multivariable | Stage, CA19-9, LDH | 8 |
28 | Chang et al. (2017) | China | 2010–2014 | Retrospective | 490 (238/252) | 63.8 | Non-Small Cell Lung Cancer (IV) | Molecular targeted, Chemo | 3.1 | NR | OS | Multivariable | BMI, Sex, Diabetes mellitus, PS, EGFR mutation, Tumor type, De novo liver metastases | 7 |
50 | Liu et al. (2017) | China | 2012–2013 | Retrospective | 162 (127/35) | 63 (38–70) | Esophageal cancer (II, III) | Chemo, Radio | 4.02 | 23.3 (8–43.7) | PFS, OS | Multivariable | cT status, Tumor stage, Tumor response | 8 |
29 | Stotz et al. (2014) | Austria | 1996–2011 | Retrospective | 372 (217/155) | 64 (27–95) | Colon cancer (II, III) | Surgery | 2.83 | 68 (1–190) | OS | Multivariable | Tumor invasion depth, Lymph node involvement, Tumor stage | 8 |
10 | Neofytou et al. (2015) | UK | 2005–2012 | Retrospective | 140 (88/52) | NR | Colorectal cancer (IV) | Surgery, Chemo | 3 | 33 (1–103) | OS | Multivariable | Distribution of lesions, Lymph node-positive primary tumor, Adjuvant chemotherapy | 8 |
30 | Kozak et al. (2017) | USA | 2005–2009 | Retrospective | 53 | NR | Colorectal Cancer (III) | Surgery | 2.6 | NR | OS | Multivariable | Age, Overall Stage, Total lymph nodes | 7 |
31 | Shibutani et al. (2018) | Japan | 2008–2016 | Retrospective | 160 (86/74) | 65 (18–89) | Colorectal cancer (IV) | Chemo, Molecular targeted | 2.96 | 21.8 (1.2–94.0) | OS | Multivariable | Sex, PS, Location of primary tumor, RAS status | 7 |
9 | Marin Hernández et al. (2018) | Spain | 2003–2016 | Retrospective | 150 | 49.8 (28–77) | Breast cancer (II, III) | Chemo | 5.46 | 24 (1–144) | OS | Multivariable | Pretreatment size, Neutrophil-to-lymphocyte ratio, Neutrophils | 7 |
32 | Xue et al. (2017) | China | 2009–2015 | Retrospective | 153 (102/51) | 60 (34–86) | Pancreatic cancer (III, IV) | Chemo | 2.8 | 8.8 (0.5–75.5) | OS | Multivariable | ECOG PS, TNM stage, CA 19-9 | 7 |
33 | Zhou et al. (2014) | China | 2006–2008 | Retrospective | 426 (304/122) | NR | Gastric cancer (II, III) | Surgery, Chemo | 4.32 | 39.58 (2.63–85.63) | OS | Multivariable | Size, Vascular/nerve infiltration, Resection margin, TNM stage, Adjuvant chemotherapy | 8 |
33 | Chan et al. (2017) | Australia | 1998–2012 | Retrospective | 740 (370/370) | NR | Colorectal Cancer (III) | Surgery, Chemo, Radio | 2.38 | NR | OS | Multivariable | Age, T Stage, N stage, Grade, MMR-BRAF status | 7 |
35 | Oh et al. (2017) | Korea | 200–2011 | Retrospective | 261 (143/118) | 65.0 (31–86) | Colorectal cancer (II) | Surgery | 3.7 | 78.0 (3–119) | OS | Multivariable | Age, Lymphatic invasion, Venous invasion, Perineural invasion, Preoperative CEA, Adjuvant chemotherapy | 8 |
37 | Kano et al. (2017) | Japan | 2003–2012 | Retrospective | 222 | NR | Head and neck cancer (III, IV) | Radio, Chemo | 3.22 | NR | OS | Multivariable | Age, Sex, Primary location, Chemotherapy | 7 |
36 | Cong et al. (2016) | China | 2007–2011 | Retrospective | 188 (147/41) | 77 (75–88) | Gastric cancer (II, III) | Surgery | 4.34 | 21.8 (1.3–92.9) | OS | Multivariable | Gender, CEA, CA19-9, Tumor site, Tumor size, TNM, Lymph node metastasis | 7 |
38 | Li et al. (2016) | China | 2012–2014 | Retrospective | 68 | NR | Pancreatic adenocarcinoma (III) | Surgery | 2.86 | NR | OS | Multivariable | ASA score, T stage, Lymph node status, TNM stage, Pathological differentiation | 7 |
11 | Qi et al. (2016) | China | 2009–2010 | Retrospective | 177 (108/69) | 58.8 | Chemo | 3 | NR | OS | Multivariable | Cancer stage, CA 19-9 | 7 |
Primary outcome: overall survival
Variables | No. of studies | Test of association | Test of heterogeneity | |||
---|---|---|---|---|---|---|
HR | 95% CI | P value | I2 (%) | P value | ||
Total | 35 | 0.578 | 0.522–0.641 | < 0.001 | 70.10 | < 0.001 |
Publication year | ||||||
≤ 2016 | 18 | 0.572 | 0.497–0.660 | < 0.001 | 67.20 | < 0.001 |
> 2016 | 17 | 0.583 | 0.499–0.681 | < 0.001 | 72.60 | < 0.001 |
Initial inclusion period | ||||||
≤ 2006 | 19 | 0.554 | 0.480–0.640 | < 0.001 | 72.90 | < 0.001 |
> 2006 | 16 | 0.604 | 0.516–0.707 | < 0.001 | 68.20 | < 0.001 |
Research region | ||||||
Asia | 28 | 0.584 | 0.520–0.656 | < 0.001 | 74.90 | < 0.001 |
Europe | 5 | 0.553 | 0.446–0.685 | < 0.001 | 0.00 | 0.712 |
America and others | 2 | 0.584 | 0.459–0.744 | < 0.001 | 0.00 | 0.596 |
Number of cases | ||||||
< 200 | 19 | 0.632 | 0.547–0.730 | < 0.001 | 63.20 | < 0.001 |
> 200 | 16 | 0.549 | 0.497–0.606 | < 0.001 | 41.30 | 0.043 |
Median age (years) | ||||||
≤ 60 | 13 | 0.585 | 0.496–0.691 | < 0.001 | 69.20 | < 0.001 |
> 60 | 13 | 0.575 | 0.488–0.679 | < 0.001 | 75.70 | < 0.001 |
NR | 9 | 0.557 | 0.427–0.727 | < 0.001 | 62.60 | 0.006 |
Tumor types | ||||||
Breast cancer | 1 | 0.47 | 0.171–1.295 | 0.144 | – | – |
Cervical carcinoma | 1 | 0.337 | 0.164–0.691 | 0.003 | – | – |
Colon cancer and rectal cancer | 13 | 0.579 | 0.516–0.650 | < 0.001 | 0.00 | 0.496 |
Ovarian cancer | 1 | 0.615 | 0.527-0.718 | < 0.001 | – | – |
Esophageal cancer | 1 | 0.495 | 0.315– 0.778 | 0.002 | – | – |
Gastric cancer | 2 | 0.664 | 0.523–0.843 | 0.001 | 0.00 | 0.622 |
Head and neck cancer | 1 | 0.28 | 0.168–0.466 | < 0.001 | – | – |
Hepatocellular carcinoma | 1 | 0.73 | 0.399–1.336 | 0.308 | – | – |
Lung cancer | 5 | 0.594 | 0.435–0.811 | 0.001 | 85.50 | < 0.001 |
Nasopharyngeal carcinoma | 2 | 0.479 | 0.406–0.566 | < 0.001 | 0.00 | 0.379 |
Pancreatic cancer | 5 | 0.588 | 0.407–0.851 | 0.005 | 67.90 | 0.014 |
Renal cancer | 2 | 0.827 | 0.755–0.906 | < 0.001 | 0.00 | 0.7 |
LMR cutoff | ||||||
< 3.0 | 9 | 0.508 | 0.444–0.582 | < 0.001 | 16.00 | 0.3 |
≥ 3.0 | 26 | 0.612 | 0.546–0.686 | < 0.001 | 69.80 | < 0.001 |
Therapeutic strategies | ||||||
Chemotherapy | 10 | 0.592 | 0.518–0.676 | < 0.001 | 31.90 | 0.153 |
Molecular targeted | 2 | 0.622 | 0.304–1.271 | 0.193 | 93.00 | < 0.001 |
Surgery | 10 | 0.683 | 0.579–0.807 | < 0.001 | 54.30 | 0.02 |
Combined therapy | 11 | 0.507 | 0.442–0.582 | < 0.001 | 37.90 | 0.097 |
Others | 2 | 0.563 | 0.400–0.794 | 0.001 | 0.00 | 0.577 |
Follow-up period (months) | ||||||
≤ 33 | 13 | 0.545 | 0.454–0.653 | < 0.001 | 67.80 | < 0.001 |
> 33 | 9 | 0.594 | 0.515–0.685 | < 0.001 | 15.60 | 0.303 |
NR | 13 | 0.606 | 0.504–0.729 | < 0.001 | 81.10 | < 0.001 |
Quality score | ||||||
< 7 | 3 | 0.753 | 0.592–0.958 | 0.021 | 83.20 | 0.003 |
≥ 7 | 32 | 0.558 | 0.504–0.619 | < 0.001 | 58.30 | < 0.001 |
Analysis of hazard ratio | ||||||
Multivariate | 32 | 0.562 | 0.503–0.628 | < 0.001 | 68.70 | < 0.001 |
Univariate | 3 | 0.755 | 0.643–0.887 | 0.001 | 23.30 | 0.272 |
Secondary outcome: progression-free survival
Variables | No. of studies | Test of association | Test of heterogeneity | |||
---|---|---|---|---|---|---|
HR | 95% CI | P value | I2 (%) | P value | ||
Total | 9 | 0.598 | 0.465–0.768 | < 0.001 | 89.00 | < 0.001 |
Publication year | ||||||
≤ 2016 | 4 | 0.526 | 0.355–0.777 | 0.001 | 83.10 | < 0.001 |
> 2016 | 5 | 0.66 | 0.470–0.881 | 0.006 | 89.60 | < 0.001 |
Initial inclusion period | ||||||
≤ 2006 | 3 | 0.502 | 0.299–0.843 | 0.009 | 88.70 | < 0.001 |
> 2006 | 6 | 0.648 | 0.47–0.882 | 0.006 | 89.60 | < 0.001 |
Nationality | ||||||
China | 8 | 0.561 | 0.466–0.675 | < 0.001 | 64.40 | 0.006 |
Japan | 1 | 1 | 0.896–1.116 | 1 | – | – |
Number of cases | ||||||
< 200 | 4 | 0.684 | 0.450–1.040 | 0.075 | 83.10 | < 0.001 |
> 200 | 5 | 0.551 | 0.429–0.707 | < 0.001 | 77.60 | 0.001 |
Median age (years) | ||||||
≤ 60 | 5 | 0.546 | 0.408–0.729 | < 0.001 | 77.00 | 0.002 |
> 60 | 4 | 0.67 | 0.462–0.971 | 0.035 | 87.70 | < 0.001 |
Tumor types | ||||||
Cervical carcinoma | 1 | 0.239 | 0.151–0.379 | < 0.001 | – | – |
Colon cancer and rectal cancer | 2 | 0.695 | 0.562–0.861 | 0.001 | 0.00 | 0.713 |
Ovarian cancer | 1 | 0.581 | 0.508–0.664 | < 0.001 | – | – |
Esophageal cancer | 1 | 0.461 | 0.31–0.685 | < 0.001 | – | – |
Lung cancer | 4 | 0.738 | 0.54–1.007 | 0.056 | 80.00 | 0.002 |
LMR cutoff | ||||||
≤ 4.0 | 4 | 0.609 | 0.546–0.680 | < 0.001 | 0.00 | 0.546 |
> 4.0 | 5 | 0.56 | 0.351–0.892 | 0.015 | 92.20 | < 0.001 |
Therapeutic strategies | ||||||
Chemotherapy | 4 | 0.62 | 0.558–0.688 | < 0.001 | 0.00 | 0.489 |
Molecular targeted | 2 | 0.793 | 0.472–1.335 | 0.384 | 84.10 | 0.012 |
Combined therapy | 3 | 0.415 | 0.241–0.716 | 0.002 | 78.40 | 0.01 |
Follow-up period (month) | ||||||
≤ 33 | 4 | 0.619 | 0.510–0.751 | < 0.001 | 14.20 | 0.321 |
> 33 | 3 | 0.457 | 0.270–0.774 | 0.004 | 85.40 | 0.001 |
NR | 2 | 0.826 | 0.55–1.239 | 0.356 | 88.50 | 0.003 |
Quality score | ||||||
< 7 | 2 | 0.826 | 0.550–1.239 | 0.356 | 88.50 | 0.003 |
≥ 7 | 7 | 0.542 | 0.435–0.674 | < 0.001 | 67.80 | 0.005 |
Analysis of hazard ratio | ||||||
Multivariate | 8 | 0.592 | 0.452–0.776 | < 0.001 | 90.40 | < 0.001 |
Univariate | 1 | 0.644 | 0.406–1.021 | 0.061 | – | – |